L & S Advisors Inc increased its holdings in shares of Zoetis Inc (NYSE:ZTS) by 226.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,267 shares of the company’s stock after purchasing an additional 21,680 shares during the quarter. L & S Advisors Inc’s holdings in Zoetis were worth $3,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in the company. Huntington National Bank increased its position in Zoetis by 3.0% in the second quarter. Huntington National Bank now owns 2,975 shares of the company’s stock worth $338,000 after buying an additional 87 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC grew its position in shares of Zoetis by 1.8% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 4,980 shares of the company’s stock worth $565,000 after purchasing an additional 89 shares in the last quarter. Intellectus Partners LLC grew its position in shares of Zoetis by 1.1% during the second quarter. Intellectus Partners LLC now owns 8,040 shares of the company’s stock worth $912,000 after purchasing an additional 91 shares in the last quarter. Rehmann Capital Advisory Group grew its position in shares of Zoetis by 4.0% during the first quarter. Rehmann Capital Advisory Group now owns 2,550 shares of the company’s stock worth $257,000 after purchasing an additional 97 shares in the last quarter. Finally, LS Investment Advisors LLC grew its position in shares of Zoetis by 0.7% during the second quarter. LS Investment Advisors LLC now owns 15,241 shares of the company’s stock worth $1,730,000 after purchasing an additional 99 shares in the last quarter. 90.25% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently issued reports on ZTS. Argus set a $140.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Wednesday, September 4th. SunTrust Banks increased their target price on Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a research report on Tuesday, August 13th. Stifel Nicolaus increased their target price on Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Guggenheim began coverage on Zoetis in a research report on Thursday, May 23rd. They set a “buy” rating and a $114.00 target price for the company. Finally, Craig Hallum increased their target price on Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Zoetis presently has an average rating of “Buy” and an average price target of $120.31.
Shares of NYSE:ZTS traded up $0.01 during trading on Friday, hitting $121.70. The company had a trading volume of 8,426 shares, compared to its average volume of 1,747,444. The stock has a market cap of $58.75 billion, a price-to-earnings ratio of 38.86, a price-to-earnings-growth ratio of 3.11 and a beta of 0.87. Zoetis Inc has a one year low of $78.90 and a one year high of $130.08. The company has a fifty day simple moving average of $122.69 and a two-hundred day simple moving average of $108.79. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.08. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. During the same period last year, the company earned $0.77 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. On average, equities research analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current year.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.